Conference programme
Day One 15 April 2008 Tuesday
08.00 Registrations and refreshments
08.30 Organiser’s welcome remarks
08.45 Guest-of-honour address
Lim Hng Kiang, Minister
Ministry of Trade & Industry, Singapore
08.55 Chairman's welcome remarks
Murali K. Prahalad, Vice President, Molecular Biology Essentials
Invitrogen Corporation, USA
09.00 Global keynote address and executive interview: The evolving biomedical
science and industry
• Market trends and drivers of the biomedical industry and crystal balling future growth
• Emerging biomedical innovation from Asia and its impact
• The evolution of the global biotech capital market: Where and how does Asia fit into the
equation
Keynote speakers:
Gordon Binder, Managing Director, Coastview Capital, USA
Founder & former CEO, Amgen Inc, USA
Philippe Kourilsky, Chair of Immunology, College de France
Former Director General, Pasteur Institute, France
Ansbert Gadick, Founder & General Partner, MPM Capital, USA
Interviewer:
Lorraine Hahn, Journalist & TV Presenter, Former TV Talk-show-host & Anchor
CNN and CNBC, Hong Kong
10.00 Morning refreshments, BioMedical Technology Showcase session & combined 
11.00 Chairman's opening remarks
Ansbert Gadick, Founder & General Partner
MPM Capital, USA
BIOMEDICAL INVESTMENT OPPORTUNITIES, CHALLENGES AND TRENDS IN ASIA
11.05 Investors’ Perspective Roundtable
This speaking panel will consist of representatives from an Asian based VC, a US-based
VC, an international private equity, a strategic corporate investor, a Europe-base
Corporate VC Fund, a Japan-based Institutional investor and a government/strategic
investor who will share their current investment focus and strategy for investments into the
biomedical and healthcare industries in Asia Pacific.
Moderator:
Ansbert Gadick, Founder & General Partner
MPM Capital, USA
Panelists:
Zhi Yang, Managing Partner
BioVeda China, China
Stephen Knight, Managing Partner
Fidelity Biosciences Group, USA
Anja Konig, Managing Director Asia Pacific
Novartis Venture Fund, Switzerland
Yi Shi, Managing Director
Lilly Asian Ventures, China
Chu Swee Yeok, Chief Executive Officer
Bio*One Capital Pte Ltd, Singapore
Alberto Bautista, Sector Partner
3i Asia Limited, Singapore
Ichiro Kawada, President
JAIC Asia Capital Pte Ltd, Singapore
12.30 Networking luncheon & showcase session
LEVERAGING ON THE ASIA ADVANTAGE
14.00 Panel Discussion: Leveraging on the opportunities presented by Asia's
exploding markets to develop a vibrant biomedical industry in Asia Pacific
• What are the key opportunities for development of innovative and high growth products &
services which address the growing and unique needs of Asian populations and how to
identify and develop successful investments in this area
• Harnessing regional expertise, market knowledge and resources to create new innovative
products and services for Asian and global markets
• Leveraging on some of the existing strengths in Asia and identifying the opportunities for
growth in the biomedical and healthcare sectors
Moderator:
Por-Hsiung Lai, Managing Director
Dephoron Group, Taiwan
Panelists:
Jean-Yves Nothias, Managing Director, Biotechnology Venture Capital
SG Asset Management Alternative Investments (SGAM AI), France
Ralf Altmeyer, President
CombinatoRx Singapore Pte Ltd, Singapore
Tan Sze Wee, Chief Executive Officer & Managing Director
Rockeby biomed, Singapore, Australia
ALTERNATIVE PARTNERING MODELS
15.00 Strategic and alternative partnering models for Biomedical ventures
• Innovative operational and financial solutions tailored to the capacity and capital needs of
emerging companies
• Alternative to common industry partnership models
• Company and product value-retaining structures
• Intellectual capital, management and financial resources that enable pharmaceutical and
biotech companies to leverage clinical development and commercial opportunities and
maximize shareholder value
Paul Casey, Vice President
NovaQuest, USA
15.30 Afternoon refreshments, showcase session &
EXIT STRATEGIES FOR INVESTORS
16.30 Panel Discussion: Planning the perfect exit strategy and the unique proposition
offered in the Asian markets
The various exit options will be discussed in this panel including Initial Public Offering (IPO)
and divestment of holdings through mergers and acquisitions. The stock exchange listing
options for biotech companies and overview of public stock exchanges and new legislation in
Asia will also be reviewed. The panel will consist of representatives from venture capital,
private equity and the banking sector familiar with the Asian and Australian listing option
and requirements.
Moderator:
Damien Lim, General Partner
BioVeda Capital, Singapore
Panelists:
Georgie H. F. Lee, Director, Equity Sales
UOB Kay Hian Pte Ltd, Singapore
Sanjay Sehgal, Managing Partner & CEO
East West Capital Partners, India, Singapore
Carrie Hillyard, Partner
CM Capital, Australia
He Guosen, Senior Investment Manager
Shenzhen Capital Group Co., Ltd, China
17.15 Chairman’s closing remarks
17.20 Close of day one
19.00 Biomedical industry awards and gala dinner
Day Two 16 April 2008 Wednesday
08.30 Registration and refreshments
08.45 Chairman’s opening remarks
REGIONAL INCENTIVES, LEGISLATIONS & GOVERNMENT POLICIES
Raising and investing capital in today’s environment requires regional knowledge and an individualised approach. Investment options often depends on the development phase of the venture, investees’ preferences, and the political and strategic value of the venture and availability of government-led incentives
9.00 Regional roundup: What are some of the key incentives, supporting legislation
and government policies related to biotech funding in the biotech hot spots and
emerging centres in Asia?
Representatives from government authorities or biotech associations from key biotech
regional economies in Asia, namely China, India, Singapore, Korea & Taiwan will provide a
national perspective on the following:
• What are the incentives provided by the individual governments to attract investment into
their countries i.e. technical/manpower and IP support, designated incubation services and
facilities, tax incentives?
• What are some government-linked funds available for catalysing and financing new ventures
and what are the eligibility criteria for these funds?
Moderator:
Sarath Naru, Managing Director
APIDC-Venture Capital Ltd, India
Panelists:
Yeoh Keat Chuan, Executive Director, Biomedical Sciences Group
Economic Development Board, Singapore
Ningni Yu, Vice President
Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., China
Chei-Hsiang Chen, Director, Biotechnology and Pharmaceutical Industries Program Office,
Ministry of Economic Affairs, Taiwan
Anna Lavelle, Chief Executive Officer
AusBiotech Ltd, Australia
10.30 Morning refreshments & showcase session
INVESTOR-INVESTEE PARTNERSHIPS
The success of a new venture often depends on the relationship and level of synergy built between the founders & management of the company and the investor/ strategic partner and is essential for the long term success of biotech ventures in today’s competitive and market-driven environment.
11.00 Case Study/ Panel Discussion: "The Amaranth story”
The innovator, co-investors and founding management of Amaranth Medical will share their
perspectives on the successful development of this multi-national biomedical venture
• Founding a company based on university technology from Singapore
• Obtaining initial seed financing
• Obtaining U.S. venture capital financing
• Operating a multi-national start-up
Moderator:
Fred M. Schwarzer, Managing Partner
Charter Life Sciences, USA
Panelists:
Freddy Y. C. Boey, Professor & Chair, School of Materials Science and Engineering
Nanyang Technological University, Singapore
Guy Heathers, Former Chief Executive Officer
Amaranth Medical Pte Ltd, Singapore
Lawrence Chin, Director of Investments
Bio*One Capital, Singapore
11.35 Case Study: Arthritis: The Trillion Dollar Dilemma – Problems & Opportunities
• The world's aging but active population demands more and better total technology
solutions
• More trained surgeons, early recognition, prevention and treatment of bones & joints
• The rise of Small Bone Innovations Inc.(SBI) in meeting unmet patient and surgeons needs
• Adapting the SBI model to Asia-PAC regional market and regulatory demands
Anthony G. Viscogliosi, Principal
Viscogliosi Bros. LLC, USA &
Chairman & Chief Executive Officer, Small Bone Innovations, Inc., USA
CAPITAL RAISING STRATEGY AND CHALLENGES
12.00 VC’s perspective on how to successfully form a relationship with US venture
firms
• Is a US VC the right financing source?
• Prospective investor selection
- Do’s and don’ts in identifying, contacting, and selecting the ‘right’ US VC
• Relationship expectations
- What to expect in deal terms, syndication
- What to expect post investment – value adding
• Case studies and lessons learnt from experience with 2 portfolio companies from UK and
Israel
Suzette Dutch, Managing Partner
Triathlon Medical Ventures, USA
12.15 Panel Discussion: “Horses for Courses”: Match making investors to investees
Seasoned VCs specialising in the life sciences sector will share valuable tips on the do’s and
don’t of fund raising for biomedical ventures and how to select the right partner to match
specific needs. Great opportunity to hear it straight from the horse’s mouth.
Moderator:
Suzette Dutch, Managing Partner
Triathlon Medical Ventures, USA
Panelists:
Elliot Parks, Managing Director
Hamilton BioVentures, USA
Fred M. Schwarzer, Managing Partner
Charter Life Sciences, USA
Anthony G. Viscogliosi, Principal
Viscogliosi Bros. LLC, USA
Hui Hsing Ma, Venture Partner
TVM Capital, Germany
12.45 Networking Luncheon & showcase session
MANAGING RISK in FINANCING THE DEAL
14.00 Managing risk while investing in early stage biomedical companies
• Due diligence prior to investing
• Managing technical, clinical, and regulatory risks
• Solving the management challenges along the way
• Sourcing additional follow-on capital
Elliot Parks, Managing Director
Hamilton BioVentures, USA
14.30 Valuation in life sciences: How to put a value on license contracts and biomedial
companies?
• Methods: DCF, rNPV, Real Options, IRR, Simulations
• Understanding price vs. value
• License deals: Valuation for structuring an comparing term sheets
• Biomedical companies: Building a framework for firm valuation
Boris Bogdan, Partner
Avance, Switzerland
15.00 Afternoon refreshments & showcase session
15.30 Small group interactive roundtable discussions
The following roundtables will bring together investors and potential investees to discuss the
financing of specific biomedical & healthcare sectors, share common experiences and
explore partnership opportunities.
A) Financing medical devices and in vitro diagnostics
Moderator:
Douglas Schein, CEO
BOOST Venture Creation, Singapore
B) Financing stem cell and regenerative medicine therapeutics
Moderator:
Gregory A. Bonfiglio, Managing Partner, Proteus Venture Partners, USA
C) Financing drug discovery and development
Moderator:
Anthony Bishop, Director
Chakra Biotech Pte Ltd & Project Manager, Merlion Pharmaceuticals, Singapore
D) Financing consumer healthcare, herbals, traditional medicines
E) Financing the establishment or expansion of biologics and pharmaceuticals
manufacturing in Asia
17.00 Chairman’s closing remarks
17.15 Close of conference
